Expression of Toll/interleukin-1 receptor (TIR)-associated protein in primary hyperparathyroidism.

Oliwia Segiet; Adam Piecuch; Marlena Brzozowa-Zasada; Mariusz Deska; Grzegorz Bula; Jacek Gawrychowski; Romuald Wojnicz

doi:10.1530/endoabs.56.P655

P655

Prev Next

Section Contents Cite

Endocrine Abstracts (2018) 56 P655 | DOI: 10.1530/endoabs.56.P655

ECE2018 Poster Presentations: Interdisciplinary Endocrinology Endocrine tumours and neoplasia (11 abstracts)

Expression of Toll/interleukin-1 receptor (TIR)-associated protein in primary hyperparathyroidism.

Oliwia Segiet ¹ , Adam Piecuch ¹ , Marlena Brzozowa-Zasada ¹ , Mariusz Deska ² , Grzegorz Buła ² , Jacek Gawrychowski ² & Romuald Wojnicz ¹

Views

Author affiliations

¹Department of Histology and Embryology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland; ²Department of General and Endocrine Surgery, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland.

Background: Primary hyperparathyroidism is one of the most common endocrine disorders caused by adenoma (80%), hyperplasia (15%) and carcinoma (5%). It is often difficult to differentiate between hyperplasia from an adenoma of a parathyroid gland. Toll/interleukin-1 receptor (TIR)-associated protein (TIRAP) is an adaptor protein for Toll-like receptors-2 and -4 (TLR2/4) which are engaged in transducing the signal to downstream molecules. Several studies have shown the increased role of this protein in pathogenesis of hyperplastic lesions and neoplasm development.

Aim: The aim of the study was to assess the immunohistochemical expression of TIRAP as a potentially useful in diagnosis of hyperplastic lesions of the parathyroid glands.

Methods: For immunohistochemistry, parathyroid specimens of patients undertaken surgery due to primary hyperparathyroidism caused by adenoma and primary hyperplasia were investigated. Frozen sections were incubated with purified mouse monoclonal antihuman antibody anti-TIRAP. The immunohistological investigations were performed by the BrightVision method from ImmunoLogic. The number of proliferating cells were counted and expressed as a mean value of at least 6 counted high power fields (HPF, x 400). The sections were counterstained with Mayer’s haematoxylin.

Results: The expression of TIRAP was significantly increased in parathyroid adenomas and hyperplasias compared to healthy parathyroid glands.

Conclusions: TIRAP might be useful in differential diagnosis between hyperplastic lesions of parathyroid gland.